Beta-blockers (All routes except ocular) (versus unexposed) updated on 12-17-2024

Jaundice / Icterus

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14051
R55687		 Xiang - Labetalol, 2020 Neonatal hyperbilirubinemia (High Serum bilirubin or more 2 mg/dL) during pregnancy (anytime or not specified) randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: Only chronic hypertension indication 3.24 [1.70;6.18] C 41/124   16/121 57 124
ref
S13811
R54140		 Chan - Labetalol, 2010 Jaundice during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 1.71 [0.47;6.19] C 6/32   5/42 11 32
ref
Total 2 studies 2.85 [1.60;5.08] 68 156
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Xiang - Labetalol, 2020Xiang - Labetalol, 2020 3.24[1.70; 6.18]5712480%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Chan - Labetalol, 2010Chan - Labetalol, 2010 1.71[0.47; 6.19]113220%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: lowROB reporting: moderate Total (2 studies) I2 = 0% 2.85[1.60; 5.08]681560.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.71[0.47; 6.19]1132 -NAChan - Labetalol, 2010 1 case control studiescase control studies 0 RCTRCT 3.24[1.70; 6.18]57124 -NAXiang - Labetalol, 2020 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.71[0.47; 6.19]1132 -NAChan - Labetalol, 2010 1 unexposed, sickunexposed, sick 3.24[1.70; 6.18]57124 -NAXiang - Labetalol, 2020 1 Tags Adjustment   - No  - No 1.71[0.47; 6.19]1132 -NAChan - Labetalol, 2010 1   - Randomisation  - Randomisation 3.24[1.70; 6.18]57124 -NAXiang - Labetalol, 2020 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.71[0.47; 6.19]1132 -NAChan - Labetalol, 2010 1   - Only chronic hypertension indication  - Only chronic hypertension indication 3.24[1.70; 6.18]57124 -NAXiang - Labetalol, 2020 1 MatchedMatched 1.71[0.47; 6.19]1132 -NAChan - Labetalol, 2010 1 All studiesAll studies 2.85[1.60; 5.08]681560%NAXiang - Labetalol, 2020 Chan - Labetalol, 2010 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.71[0.47; 6.19]1132 -NAChan - Labetalol, 2010 1 unexposed, sick controlsunexposed, sick controls 3.24[1.70; 6.18]57124 -NAXiang - Labetalol, 2020 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Magee (Neonatal jaundice)Magee (Neonatal jaundice) 0.56[0.24; 1.28]0%-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT2 Magee (Neonatal jaundice)Magee (Neonatal jaundice) 1.32[0.65; 2.68]0%-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT2 Abalos (Neonatal jaundice (RCT versus no anti ...Abalos (Neonatal jaundice (RCT versus no antihypertensive drugs/placebo)) 0.53[0.19; 1.47]NA-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT1 metaPregmetaPreg 2.85[1.60; 5.08]0%156----Xiang - Labetalol, 2020 Chan - Labetalol, 2010 20.510.01.0